US Biomax, Inc.

PR483a

Prostate cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases/48 cores, replacing PR483

Microarray Panel:Prostate adenocarcinoma tissue microarray, containing 40 cases of prostate adenocarcinoma, plus 8 normal prostate tissue, single core per case
Cores:48
Cases:48
Layout:8 cols × 6 rows
Core Diameter:1.5 mm
Thickness:5 µm
Quality Control:Anti-Actin confirmed
Applications:Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page.
Notes:Unless specified, all TMA slides are not coated with extra layer of paraffin (tissue cores can be easily seen on the glass), so there is no need to bake, can be directly put into xylene for de-paraffin procedure.


Microarray Panel Display

 
Slide Label: US Biomax, Inc. Tissue Array
12345678 
A Pro Pro Pro Pro Pro Pro Pro Pro  
B Pro Pro Pro Pro Pro Pro Pro Pro  
C Pro Pro Pro Pro Pro Pro Pro Pro  
D Pro Pro Pro Pro Pro Pro Pro Pro  
E Pro Pro Pro Pro Pro Pro Pro Pro  
F Pro Pro Pro Pro Pro Pro Pro Pro Marked point
Legend: Pro - Prostate

- Malignant tumor, - Malignant tumor (stage I), - Malignant tumor (stage II), - Malignant tumor (stage III), - Malignant tumor (stage IV), - Normal tissue

Specification Sheet

Pos No. Sex Age Organ Pathology diagnosis Grade Stage Gleason Grade Gleason Score TNM Type †
A1 1 M 72 Prostate Adenocarcinoma 1 II 1 1+2 T2N0M0 Malignant
A2 2 M 64 Prostate Adenocarcinoma 1 I 1 1+2 T1N0M0 Malignant
A3 3 M 60 Prostate Adenocarcinoma 1 IV 1 1+1 T4N1M1c Malignant
A4 4 M 66 Prostate Adenocarcinoma 1 IV 2 1+2 T3N1M1c Malignant
A5 5 M 65 Prostate Adenocarcinoma 1 II 2 1+2 T2N0M0 Malignant
A6 6 M 75 Prostate Adenocarcinoma 1 IV 2 1+2 T2N1M1c Malignant
A7 7 M 71 Prostate Adenocarcinoma 2–3 II 5 4+5 T2N0M0 Malignant
A8 8 M 78 Prostate Adenocarcinoma 2 IV 3 2+3 T3N2M1 Malignant
B1 9 M 74 Prostate Adenocarcinoma 2 IV 2 2+3 T4N1M1c Malignant
B2 10 M 69 Prostate Adenocarcinoma 2 III 2 2+3 T3N0M0 Malignant
B3 11 M 75 Prostate Adenocarcinoma 2 IV 3 3+4 T4N1M1 Malignant
B4 12 M 69 Prostate Adenocarcinoma 2 II 2 2+4 T2N0M0 Malignant
B5 13 M 73 Prostate Adenocarcinoma 2 IV 2 2+4 T3N1M1c Malignant
B6 14 M 56 Prostate Adenocarcinoma 2–3 II 4 4+5 T2N0M0 Malignant
B7 15 M 73 Prostate Adenocarcinoma 2 II 3 2+3 T2N0M0 Malignant
B8 16 M 70 Prostate Adenocarcinoma 2 III 3 3+4 T3N0M0 Malignant
C1 17 M 20 Prostate Adenocarcinoma 1–2 III 2 2+3 T3N0M0 Malignant
C2 18 M 61 Prostate Adenocarcinoma 1–2 III 2 2+3 T3N1M0 Malignant
C3 19 M 73 Prostate Adenocarcinoma 2 III 4 2+4 T3N0M0 Malignant
C4 20 M 82 Prostate Adenocarcinoma 2 II 3 3+4 T2N0M0 Malignant
C5 21 M 75 Prostate Adenocarcinoma 3 IV 3 3+4 T4N1M1 Malignant
C6 22 M 78 Prostate Adenocarcinoma 3 IV 4 4+5 T4N1M1b Malignant
C7 23 M 60 Prostate Adenocarcinoma 2 IV 4 4+3 T3N1M1b Malignant
C8 24 M 73 Prostate Adenocarcinoma 2 IV 4 4+3 T3N1M1b Malignant
D1 25 M 62 Prostate Adenocarcinoma 2 IV 4 4+3 T3N1M1b Malignant
D2 26 M 51 Prostate Adenocarcinoma 2 II 4 4+2 T2N0M0 Malignant
D3 27 M 62 Prostate Adenocarcinoma 3 II 4 5+4 T2N0M0 Malignant
D4 28 M 60 Prostate Adenocarcinoma 2 IV 3 3+4 T3N1M0 Malignant
D5 29 M 68 Prostate Adenocarcinoma 2 II 3 3+4 T2N0M0 Malignant
D6 30 M 64 Prostate Adenocarcinoma 3 IV 4 4+4 T3N0M1b Malignant
D7 31 M 66 Prostate Adenocarcinoma 3 II 4 4+5 T2N0M0 Malignant
D8 32 M 87 Prostate Adenocarcinoma 3 II 5 5+5 T2N0M0 Malignant
E1 33 M 81 Prostate Adenocarcinoma 3 III 4 5+4 T3aN0M0 Malignant
E2 34 M 80 Prostate Adenocarcinoma 3 IV 5 5+5 T4N1M1c Malignant
E3 35 M 76 Prostate Adenocarcinoma 3 IV 5 5+5 T3N1M1b Malignant
E4 36 M 73 Prostate Adenocarcinoma 3 IV 5 5+5 T4N1M1c Malignant
E5 37 M 63 Prostate Adenocarcinoma 3 IV 5 5+5 T2N1M1b Malignant
E6 38 M 67 Prostate Adenocarcinoma 3 II 5 5+5 T2N0M0 Malignant
E7 39 M 65 Prostate Adenocarcinoma 3 IV 5 5+5 T2N1M1 Malignant
E8 40 M 64 Prostate Adenocarcinoma 3 II 5 5+5 T2N0M0 Malignant
F1 41 M 35 Prostate Normal prostate tissue Normal
F2 42 M 43 Prostate Normal prostate tissue Normal
F3 43 M 19 Prostate Normal prostate tissue Normal
F4 44 M 46 Prostate Normal prostate tissue Normal
F5 45 M 40 Prostate Normal prostate tissue Normal
F6 46 M 28 Prostate Normal prostate tissue Normal
F7 47 M 33 Prostate Normal prostate tissue Normal
F8 48 M 37 Prostate Normal prostate tissue Normal
F 55 liver Hepatocellular liver cancer (tissue marker) 3 T3N0M0 Malignant

† For precise diagnosis, refer to pathology description.

**The grade 1-3 (or I-III) in Pathology Diagnosis is equivalent to well-differentiated, moderately-differentiated or poorly differentiated, respectively, under microscope.
Grade 1 or well-differentiated: Cells appear normal and are not growing rapidly.
Grade 2 or moderately-differentiated: Cells appear slightly different than normal.
Grade 3 or poorly differentiated: Cells appear abnormal and tend to grow and spread more aggressively.
Grade 4 or undifferentiated: *(for certain tumors), features are not significantly distinguishing to make it look any different from undifferentiated cancers which occur in other organs.

TNM grading:

T - Primary tumor
Tx - Primary tumor cannot be assessed
T0 - No evidence of primary tumor
Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
T1 - Tumor invades submucosa
T2 - Tumor invades muscularis propria
T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

N - Regional lymph nodes
Nx - Regional lymph nodes cannot be assessed
N0 - No regional lymph node metastasis
N1 - Metastasis in 1 to 3 regional lymph nodes
N2 - Metastasis in 4 or more regional lymph nodes

M - Distant metastasis
Mx - Distant metastasis cannot be assessed
M0 - No distant metastasis
M1 - Distant metastasis

Find overlapping cases with this tissue array: